Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Jan;39(1):107-108.
doi: 10.1007/s40263-024-01134-8. Epub 2024 Nov 22.

Comment on "Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population"

Xin Zhou  1   2 , Aiping Zhang  1 , Riyang Lin  3   4
Affiliations
Comment

Comment on "Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population"

Xin Zhou et al. CNS Drugs. 2025 Jan.

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: Funded by Grants-in-Aid from Zhejiang Provincial Traditional Chinese Medicine Science and Technology Plan (project 2023ZL110 and project 2024ZL110). Conflict of interest: The authors have no conflicts of interest to declare. Ethics approval: Not applicable. Consent to participate: Not applicable. Consent for publication: Not applicable Availability of data and material: Not applicable. Code availability: Not applicable. Author contributions: Conceptualization was carried out by Xin Zhou and Riyang Lin; supervision was performed by Aiping Zhang and Riyang Lin. The first draft of the manuscript was written by Xin Zhou and Riyang Lin. The review and editing were done by Xin Zhou, Aiping Zhang and Riyang Lin. All authors read and approved the final manuscript.

Comment on

References

    1. Kouga T, Miwa T, Sunami K, Itoh Y. Effectiveness of anti-calcitonin gene-related peptide medication in vestibular migraine: a retrospective cohort study in an Asian population. CNS Drugs. 2024;38(8):637–48. https://doi.org/10.1007/s40263-024-01094-z . - DOI - PubMed
    1. Arai YC, Yasui H, Isai H, Kawai T, Nishihara M, Sato J, Ikemoto T, Inoue S, Ushida T. The review of innovative integration of Kampo medicine and Western medicine as personalized medicine at the first multidisciplinary pain center in Japan. EPMA J. 2014;5(1):10. https://doi.org/10.1186/1878-5085-5-10.PMID:25057332;PMCID:PMC4107627 . - DOI - PubMed - PMC
    1. Takeshima T, Sakai F, Wang X, et al. Cost effectiveness of fremanezumab in episodic and chronic migraine patients from a Japanese healthcare perspective. Pharmacoeconomics. 2024;42(7):811–22. https://doi.org/10.1007/s40273-024-01380-0 . - DOI - PubMed - PMC
    1. Takeshima T, Wan Q, Zhang Y, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20(1):111. https://doi.org/10.1186/s10194-019-1062-4 . - DOI - PubMed - PMC
    1. Ihara K, Takizawa T, Watanabe N, Nakahara J, Martelletti P. Potential benefits and possible risks of CGRP-targeted multitherapy in migraine. Expert Opin Drug Metab Toxicol. 2024;20(1–2):1–4. https://doi.org/10.1080/17425255.2024.2316131 . - DOI - PubMed

LinkOut - more resources